← Leaderboards
Hong-Yu Li
University Of California, San Francisco
$3,813,256
Attributed
$8,114,391
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,114,391 · 5
By mechanism
R01$8,074,391 · 4
R41$40,000 · 1
Top collaborators
- Neil P Shah9 shared
- Neil Mcdonald5 shared
- Massimo Santoro5 shared
- Hui-Kuan Lin4 shared
- Brendan Andrew Frett1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Neil P Shah$6,146,823
- Catherine Choy Smith$4,365,274
- Michelle Mintz$159,993
- Conor Caffrey$4,887,893
- Mallar Bhattacharya$3,850,848
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDesignCellsIn VitroIn VivoBindingMutationTherapeutic AgentsToxic EffectPharmaceutical PreparationsMutantSeriesMouse ModelDoseKinase InhibitorPhosphotransferasesResistanceProteinsBiological AvailabilityOralNovel TherapeuticsRoentgen RaysPropertyDrug Development
Grant awards (19)
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$652,744
R01 · FY2025 · CA
Drug Development of Skp2 PROTACs in Cancer$643,253
R01 · FY2025 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$620,109
R01 · FY2024 · CA
Drug Development of Skp2 PROTACs in Cancer$611,086
R01 · FY2024 · CA · contact PI
Drug Development of Skp2 PROTACs in Cancer$658,049
R01 · FY2023 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$639,689
R01 · FY2023 · CA
Drug Development of Skp2 PROTACs in Cancer$1
R01 · FY2023 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$642,786
R01 · FY2022 · CA
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$685,777
R01 · FY2021 · CA
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$276,428
R01 · FY2019 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$358,560
R01 · FY2018 · CA · contact PI
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$284,978
R01 · FY2018 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$358,560
R01 · FY2017 · CA · contact PI
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$284,978
R01 · FY2017 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$370,810
R01 · FY2016 · CA · contact PI
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$309,478
R01 · FY2016 · CA · contact PI
Synactix Pharmaceuticals I-Corps Application$40,000
R41 · FY2016 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$369,332
R01 · FY2015 · CA · contact PI
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$307,773
R01 · FY2015 · CA · contact PI